Additional Immunotherapies

Exploring Platform Versatility

DNAtrix is developing novel pipeline candidates for a range of tumors by leveraging its versatile platform technology.

By arming DNAtrix’s vectors with powerful immune modulators, such as T cell agonists, Treg antagonists, cytokines, and checkpoint inhibitors, the company is developing a unique pipeline of oncology therapies based on its virus-driven immunotherapy platform.

The first candidates, expressing members of the TNF receptor superfamily that enhance T-cell activity, show remarkable efficacy in animal models of cancer, including breast, melanoma, brain and lung. 

DNAtrix is continuing to expand its pipeline with additional potent molecules and approaches to treat cancers that are resistant to currently available therapies.